PEGylated and Acylated Elabela Analogues Show Enhanced Receptor Binding, Prolonged Stability, and Remedy of Acute Kidney Injury

Chao Wang,Mingrui Xiong,Chen Yang,Dong Yang,Jiaojiao Zheng,Yu Fan,Shun Wang,Yongkang Gai,Xiaoli Lan,Hong Chen,Ling Zheng,Kun Huang
DOI: https://doi.org/10.1021/acs.jmedchem.0c01913
IF: 8.039
2020-12-08
Journal of Medicinal Chemistry
Abstract:Acute kidney injury (AKI), mostly caused by renal ischemia–reperfusion (I/R) injury and nephrotoxins, is characterized by rapid deterioration in renal-functions without effective drug treatment available. Through activation of a G protein-coupled receptor APJ, a furin-cleaved fragment of Elabela (ELA[22-32], E11), an endogenous APJ ligand, protects against renal I/R injury. However, the poor plasma stability and relatively weak APJ-binding ability of E11 limit its application. To address these issues, we rationally designed and synthesized a set of E11 analogues modified by palmitic acid (Pal) or polyethylene glycol; improved plasma stability and APJ-binding capacity of these analogues were achieved. In cultured renal tubular cells, these analogues protected against hypoxia-reperfusion or cisplatin-caused injury. For renal I/R-injured mice, these analogues showed improved reno-protective effects than E11; notably, Pal-E11 showed therapeutic effects at 24 h post I/R injury. These results present ELA analogues as potential therapeutic options in managing AKI.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01913?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01913</a>.Peptide sequence, binding Ki, and cAMP contents of analogues; primer sequence; molecular structure, purity, and mass spectrum of peptides; FTIR assays of analogues; half-life of E11 analogues in human plasma; <i>in vivo</i> pharmacokinetic analysis of E11 and Pal-E11; APJ binding curves of analogues; effects of analogues on inhibiting I/R injury-induced apoptosis, necroptosis in the kidney; effects of analogues on inhibiting H/R- and Cisplatin-induced injury in NRK-52E cells; and Pal-E11 intervention inhibits I/R injury-induced apoptosis and necroptosis in the kidney (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01913/suppl_file/jm0c01913_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.
chemistry, medicinal
What problem does this paper attempt to address?